Myers et al., 2003 - Google Patents
The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis CMyers et al., 2003
- Document ID
- 15585106986049989137
- Author
- Myers R
- Patel K
- Pianko S
- Poynard T
- McHutchison J
- Publication year
- Publication venue
- Journal of Viral Hepatitis
External Links
Snippet
The response to antiviral therapy and the rate of fibrosis progression in chronic hepatitis C virus (HCV) infection are related to common factors, including age and gender. The aim of this study was to evaluate the relationship between the rate of fibrosis progression and the …
- 206010016654 Fibrosis 0 title abstract description 79
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Myers et al. | The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C | |
Kalantar-Zadeh et al. | Hepatitis C virus and death risk in hemodialysis patients | |
Imazeki et al. | Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus‐infected and hepatitis C virus‐cleared patients | |
Chemello et al. | Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C | |
Seeff et al. | 45-year follow-up of hepatitis C virus infection in healthy young adults | |
Rao et al. | Distribution and clinical correlates of viral and host genotypes in C hinese patients with chronic hepatitis C virus infection | |
Miyaki et al. | Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients | |
Booth et al. | Clinical guidelines on the management of hepatitis C | |
Alazawi et al. | Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection | |
Enomoto et al. | Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | |
Park et al. | High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels | |
Pardo et al. | Comparative study between occult hepatitis C virus infection and chronic hepatitis C | |
Pradat et al. | Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications | |
HUANG et al. | Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan | |
Kamal et al. | Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis | |
Kosaka et al. | Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 | |
Yu et al. | A randomized trial of 24‐vs. 48‐week courses of PEG interferon α‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis C patients: a pilot study in Taiwan | |
Nguyen et al. | Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6 | |
Papatheodoridis et al. | Impact of interferon‐alpha therapy on liver fibrosis progression in patients with HBeAg‐negative chronic hepatitis B | |
Hsu et al. | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis‐related complications (Taiwanese chronic hepatitis C cohort) | |
Hung et al. | Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response | |
Lao et al. | Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys | |
YEN et al. | Mutations in the interferon sensitivity‐determining region (nonstructural 5A amino acid 2209–2248) in patients with hepatitis C‐1b infection and correlating response to combined therapy of pegylated interferon and ribavirin | |
Bonny et al. | Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study | |
Kenny-Walsh | The natural history of hepatitis C virus infection |